null

null

null

null

null

null

null

null

null

Near-zero debt; cash-funded clinical-stage biotech with ~$400M+ cash runway; 20% rate rise has negligible P&L impact

Minimal; no material floating-rate debt; higher rates modestly reduce interest income on cash holdings but immaterial to operations

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Chinese API/raw material sourcing for cell therapy inputs; 2) U.S.-EU leukapheresis equipment and GMP reagent supply concentration

Primarily U.S.-focused clinical stage; negligible international revenue; sovereign currency devaluation risk is essentially zero currently

Operations and trials predominantly U.S.-based; no material international revenue markets; currency devaluation exposure is near-null

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; single or dual CDMOs (e.g., Thermo Fisher/Wuxi-type partners) for CAR-T manufacturing represent non-substitutable critical path dependencies

Clinical-stage biopharma; no commercial product yet; revenue from grants/collaborations; cloud disruption would delay but not destroy operations

Secondary model: partnership/licensing revenue; cloud termination would impair bioinformatics and data pipelines but core IP is not cloud-native

Moderate-high API coupling risk in genomic data platforms and CDMO manufacturing workflows; switching CDMO mid-trial is 12-18 month delay risk

Low Howey risk; revenue model is drug development/licensing, not an investment contract; equity is standard biotech stock, not a token scheme

Very High

Moderate; clinical trial patient data subject to GDPR (EU trial sites) and HIPAA/CCPA; compliance infrastructure standard for Phase 2/3 biotech

Low antitrust risk; pre-commercial, niche CAR-T autoimmune space; no dominant market position to attract regulatory scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% non-recurring today; revenue is milestone/collaboration-based; no subscription or retainer revenue until commercial launch

Future monetization via drug sales (transactional/reimbursement) and licensing milestones; no recurring SaaS-type revenue stream present

Drug pricing will follow specialty/rare-disease model (~$300K-$500K per CAR-T course); pricing power dependent on clinical differentiation and payer negotiations

Moderate-high potential; CAR-T for autoimmune diseases has limited competition; pricing power contingent on Phase 3 outcomes and FDA approval

Post-commercialization target gross margins ~70-80% (typical cell therapy after COGS optimization); currently pre-revenue so margins are negative

No free-rider risk; single-course curative therapy model means churn is structurally irrelevant; patient re-treatment rate is the relevant metric

Headcount-sublinear at scale; clinical and manufacturing ops scale with trials but commercial launch requires modest sales force; R&D spend dominates now

Marginal cost of growth is capital-intensive pre-approval (trials, CMC); post-approval, CDMO variable manufacturing cost drives marginal cost, not headcount

Not applicable; Kyverna is not a franchise business model

At 10x scale (post-approval), CAC would be physician/KOL education-driven; patient identification via rheumatology/neurology referral networks; CAC likely $5K-$15K per patient

No meaningful network effects; CAR-T therapy value does not increase with more users; competitive moat is IP, manufacturing know-how, and clinical data

AI displacement risk low for core manufacturing; AI may accelerate patient identification and biomarker analysis but does not threaten core cell therapy value chain

Moderate-high recession resistance; severe autoimmune and neurological diseases create inelastic demand; reimbursement-dependent, insulating from consumer spending cycles

Institutional: hospitals, academic medical centers, and specialty infusion centers administering CAR-T therapies

Payers (commercial insurers, CMS/Medicaid) as economic buyers; high customer concentration risk given limited certified treatment centers

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated to future-state: clinical trial execution, CMC development, and manufacturing scale-up; no legacy infrastructure drag; burn rate ~$150-200M/year

0001994702

KYTX